Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCSN69)

Drug Name

PT2385 Drug Info

Synonyms

ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A

Indication

Disease Entry	ICD 11	Status	REF
Recurrent glioblastoma	2A00.00	Phase 2	[1]
Von hippel-lindau disease	5A75	Phase 2	[1]
Brain cancer	2A00	Investigative	[2]

Cross-matching ID

PubChem CID: 91754484
CAS Number: CAS 1672665-49-4
TTD Drug ID: DMCSN69

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hypoxia-inducible factor 2 alpha (HIF-2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Belzutifan	DML1KTO	Von hippel-lindau disease	5A75	Approved	[1]
------------------------------------------------------------------------------------

Drug(s) Targeting HIF2-alpha messenger RNA (EPAS1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARO-HIF2	DMV5PEK	Renal cell carcinoma	2C90	Phase 1	[4]
ISIS 222041	DMS03TR	Discovery agent	N.A.	Investigative	[5]
ISIS 222035	DMQY2EA	Discovery agent	N.A.	Investigative	[5]
ISIS 222039	DMVL1SN	Discovery agent	N.A.	Investigative	[5]
ISIS 222001	DMD7HA3	Discovery agent	N.A.	Investigative	[5]
ISIS 222043	DM26M7E	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting HIF1-alpha messenger RNA (HIF1A mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol	DM15P2G	Discovery agent	N.A.	Investigative	[6]
ISIS 298697	DM0WH1L	Discovery agent	N.A.	Investigative	[5]
ISIS 298744	DM8VMQ4	Discovery agent	N.A.	Investigative	[5]
ISIS 298746	DMHOJ0Z	Discovery agent	N.A.	Investigative	[5]
ISIS 298745	DM9YMPI	Discovery agent	N.A.	Investigative	[5]
ISIS 298743	DMD3NSQ	Discovery agent	N.A.	Investigative	[5]
ISIS 298702	DM4L7NE	Discovery agent	N.A.	Investigative	[5]
ISIS 298700	DM3DE98	Discovery agent	N.A.	Investigative	[5]
ISIS 175510	DMPAXR4	Discovery agent	N.A.	Investigative	[5]
ISIS 298699	DMB28JW	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HIF1-alpha messenger RNA (HIF1A mRNA)	TTSN6QU	HIF1A_HUMAN	Inhibitor	[1]
HIF2-alpha messenger RNA (EPAS1 mRNA)	TTWPA54	EPAS1_HUMAN	Inhibitor	[3]
Hypoxia-inducible factor 2 alpha (HIF-2A)	TTDMLNT	EPAS1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Hypoxia-inducible factor 2: a novel target in gliomas.Future Med Chem. 2018 Sep 1;10(18):2227-2236.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	National Cancer Institute Drug Dictionary (drug name ARO-HIF2).
5	US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
6	Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6305-10.